CIRM Clinical Trial Stage Projects is a grant from the California Institute for Regenerative Medicine (CIRM) that funds the clinical development of stem cell-based and genetic therapy approaches for treating diseases with unmet medical needs. The CLIN2 Awards aim to expedite clinical development toward late-stage trials by promoting innovative trial designs and incentivizing pre-commercialization strategies.

Applications for the current CLIN2 cycle are due April 30, 2026, at 2 PM PT. Funded projects must include a comprehensive clinical development strategy aimed at attaining marketing approval and ensuring clinical trial demographics match the broader patient population. Eligible applicants are developers of stem cell-based and genetic therapies pursuing commercialization pathways in California and globally.

Guiding principles focus on transformative therapeutic impact, patient access, and broad disease representation.

Clinical Trial Stage – CIRM The mission of the California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. CIRM’s Clinical Trial funding program supports the clinical development of stem cell-based and genetic therapy approaches for treatment of diseases with unmet medical needs.

Funded projects are expected to have a comprehensive clinical development strategy aimed at attaining marketing approval while ensuring that clinical trial demographics match those of the larger patient population. The clinical development strategy should include stage-appropriate pre-commercialization activities, including planning to ensure that approved treatments are accessible and affordable.

CLIN2 Awards: Funding Opportunity for Clinical Trials Important Update: New Application Selection Process CIRM’s Board approved eliminating the preference-based scoring for volume control. CIRM will now apply program-specific guiding principles throughout the application process, beginning with applications due April 30.

CLIN2 principles will focus on the transformative impact of therapies, patient access, and broad disease representation. An updated Program Announcement , Quick Guide , and Short Video Guide about the CLIN2-specific process changes are available. CLIN2 applications are now open.

Applications are due April 30, 2026, at 2 PM (PT). Visit the CLIN2 Awards page on our website for more information about the CLIN2 Awards, including deadlines, requirements, webinar information, and FAQs. The CLIN2 Awards aim to expedite clinical development towards late-stage trials by promoting innovative trial designs and incentivizing strategies for stage-appropriate market access and pre-commercialization activities.

Download the CLIN2 Program Announcement for more details regarding award eligibility, review criteria, and application information. CLIN2: Program Announcement [Updated April 3, 2026] To Submit an Application: 1. Go to the Grants Management Portal 2.

After logging in, click on the Menu tab Select the tab labeled “Open Programs” under the section labeled “RFAs and Programs Open for Applications,” click on the “ Start a Grant Application ” link for your selected program. 3. Complete each section of the Application Click on the appropriate link and follow the posted instructions.

Proposal templates can be located and submitted under the “ Uploads ” section. 4. To submit your Application Click on the “ Done with Application ” button.

The “ Done with Application ” button will be enabled when all the mandatory sections have been completed. Please note that once this has been selected, you will no longer be able to make changes to your application. 5.

To confirm submission of your Application Select the tab labeled “ Your Applications ” and check the table under the section labeled “ Your Submitted Applications. ” You will see your application number and project title listed once the submission process has been completed.